stoxline Quote Chart Rank Option Currency Glossary
  
Entrada Therapeutics, Inc. (TRDA)
16.78  -0.1 (-0.59%)    07-19 13:36
Open: 16.98
High: 17.07
Volume: 20,571
  
Pre. Close: 16.88
Low: 16.685
Market Cap: 623(M)
Technical analysis
2024-07-19 1:23:25 PM
Short term     
Mid term     
Targets 6-month :  21.22 1-year :  24.78
Resists First :  18.17 Second :  21.22
Pivot price 15.88
Supports First :  15.46 Second :  13.78
MAs MA(5) :  17.29 MA(20) :  15.52
MA(100) :  14.17 MA(250) :  14.69
MACD MACD :  0.6 Signal :  0.4
%K %D K(14,3) :  72.2 D(3) :  79.7
RSI RSI(14): 59.8
52-week High :  18.17 Low :  10.75
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ TRDA ] has closed below upper band by 32.8%. Bollinger Bands are 116.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 17.68 - 17.83 17.83 - 17.93
Low: 16.38 - 16.53 16.53 - 16.64
Close: 16.68 - 16.92 16.92 - 17.08
Company Description

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Headline News

Thu, 18 Jul 2024
Natarajan Sethuraman Sells 638 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock - American Banking and Market News

Wed, 17 Jul 2024
Entrada Therapeutics, Inc. (NASDAQ:TRDA) CEO Dipal Doshi Sells 1,600 Shares of Stock - Defense World

Tue, 16 Jul 2024
Natarajan Sethuraman Sells 600 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock - MarketBeat

Fri, 12 Jul 2024
Entrada Therapeutics (TRDA) Moves 10.4% Higher: Will This Strength Last? - Yahoo Canada Finance

Fri, 12 Jul 2024
Institutional investors must be pleased after a 22% gain last week that adds to Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) one-year returns - Simply Wall St

Fri, 12 Jul 2024
Entrada Therapeutics (NASDAQ:TRDA) Shares Down 3.6% - MarketBeat

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 34 (M)
Shares Float 17 (M)
Held by Insiders 13 (%)
Held by Institutions 70.7 (%)
Shares Short 1,670 (K)
Shares Short P.Month 1,660 (K)
Stock Financials
EPS 0.68
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 8.52
Profit Margin 14.4 %
Operating Margin 35.7 %
Return on Assets (ttm) 3 %
Return on Equity (ttm) 9.4 %
Qtrly Rev. Growth 134 %
Gross Profit (p.s.) 0
Sales Per Share 4.82
EBITDA (p.s.) 0.79
Qtrly Earnings Growth 0 %
Operating Cash Flow -89 (M)
Levered Free Cash Flow -12 (M)
Stock Valuations
PE Ratio 24.43
PEG Ratio 0
Price to Book value 1.97
Price to Sales 3.49
Price to Cash Flow -6.39
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android